DL 06002

Drug Profile

DL 06002

Alternative Names: DL06002

Latest Information Update: 26 Jul 2007

Price : $50

At a glance

  • Originator DanioLabs
  • Class Antiparkinsonians
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperhidrosis

Most Recent Events

  • 03 Jul 2006 Phase-I clinical trials in Hyperhidrosis in United Kingdom (unspecified route)
  • 03 Jul 2006 DanioLabs has initiated enrolment in a phase I trial for hyperhidrosis in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top